目次

Table of Contents

Executive Summary
Market Overview

Market Landscape
Market ecosystem
alue Chain Analysis

Market Sizing
Market definition
Market segment analysis
Market size 2021
Market outlook: Forecast for 2020 - 2025

Five Forces Analysis
Five Forces Summary
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition

Market Segmentation by Indication
Market segments
Comparison by Indication
Sickle cell anemia - Market size and forecast 2020-2025
Sickle beta thalassemia - Market size and forecast 2020-2025
Others - Market size and forecast 2020-2025
Market opportunity by Indication

Customer landscape
Overview

Geographic Landscape
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2020-2025
Europe - Market size and forecast 2020-2025
Asia - Market size and forecast 2020-2025
ROW- Market size and forecast 2020-2025
Key leading countries
Market opportunity By Geographical Landscape

Drivers, Challenges, and Trends
Market drivers
Market challenges
Market trends

Vendor Landscape
Overview
Landscape disruption
Competitive Scenario

Vendor Analysis
Vendors covered
Market positioning of vendors
Addmedica SAS
Bristol-Myers Squibb Co.
Chiesi Pharmaceuticals BV
CRISPR Therapeutics AG
Emmaus Life Sciences Inc.
Global Blood Therapeutics Inc.
GlycoMimetics Inc.
Medunik USA
Novartis AG
Pfizer Inc.

Appendix
Scope of the report
Currency conversion rates for US$
Research Methodology
List of abbreviations

1: Key Finding 1
2: Key Finding 2
3: Key Finding 3
4: Key Finding 5
5: Key Finding 6
6: Key Finding 7
7: Key Finding 8
8: Parent market
9: Market characteristics
10: Offerings of vendors included in the market definition
11: Market segments
12: Global - Market size and forecast 2020 - 2025 ($ million)
13: Global market: Year-over-year growth 2020 - 2025 (%)
14: Five forces analysis 2020 & 2025
15: Bargaining power of buyers
16: Bargaining power of suppliers
17: Threat of new entrants
18: Threat of substitutes
19: Threat of rivalry
20: Market condition - Five forces 2020
21: Indication - Market share 2020-2025 (%)
22: Comparison by Indication
23: Sickle cell anemia - Market size and forecast 2020-2025 ($ million)
24: Sickle cell anemia - Year-over-year growth 2020-2025 (%)
25: Sickle beta thalassemia - Market size and forecast 2020-2025 ($ million)
26: Sickle beta thalassemia - Year-over-year growth 2020-2025 (%)
27: Market opportunity by Indication
28: Customer landscape
29: Market share By Geographical Landscape 2020-2025 (%)
30: Geographic comparison
31: North America - Market size and forecast 2020-2025 ($ million)
32: North America - Year-over-year growth 2020-2025 (%)
33: Europe - Market size and forecast 2020-2025 ($ million)
34: Europe - Year-over-year growth 2020-2025 (%)
35: Asia - Market size and forecast 2020-2025 ($ million)
36: Asia - Year-over-year growth 2020-2025 (%)
37: ROW - Market size and forecast 2020-2025 ($ million)
38: ROW - Year-over-year growth 2020-2025 (%)
39: Key leading countries
40: Market opportunity By Geographical Landscape ($ million)
41: Impact of drivers and challenges
42: Vendor landscape
43: Landscape disruption
44: Industry risks
45: Vendors covered
46: Market positioning of vendors
47: Addmedica SAS - Overview
48: Addmedica SAS - Product and service
49: Addmedica SAS - Key offerings
50: Addmedica SAS - Key customers
51: Addmedica SAS - Segment focus
52: Bristol-Myers Squibb Co. - Overview
53: Bristol-Myers Squibb Co. - Product and service
54: Bristol-Myers Squibb Co. - Key offerings
55: Bristol-Myers Squibb Co. - Key customers
56: Bristol-Myers Squibb Co. - Segment focus
57: Chiesi Pharmaceuticals BV - Overview
58: Chiesi Pharmaceuticals BV - Product and service
59: Chiesi Pharmaceuticals BV - Key offerings
60: Chiesi Pharmaceuticals BV - Key customers
61: Chiesi Pharmaceuticals BV - Segment focus
62: CRISPR Therapeutics AG - Overview
63: CRISPR Therapeutics AG - Business segments
64: CRISPR Therapeutics AG - Key offerings
65: CRISPR Therapeutics AG - Key customers
66: CRISPR Therapeutics AG - Segment focus
67: Emmaus Life Sciences Inc. - Overview
68: Emmaus Life Sciences Inc. - Business segments
69: Emmaus Life Sciences Inc. - Key offerings
70: Emmaus Life Sciences Inc. - Key customers
71: Emmaus Life Sciences Inc. - Segment focus
72: Global Blood Therapeutics Inc. - Overview
73: Global Blood Therapeutics Inc. - Business segments
74: Global Blood Therapeutics Inc. - Key offerings
75: Global Blood Therapeutics Inc. - Key customers
76: Global Blood Therapeutics Inc. - Segment focus
77: GlycoMimetics Inc. - Overview
78: GlycoMimetics Inc. - Business segments
79: GlycoMimetics Inc. - Key offerings
80: GlycoMimetics Inc. - Key customers
81: GlycoMimetics Inc. - Segment focus
82: Medunik USA - Overview
83: Medunik USA - Product and service
84: Medunik USA - Key offerings
85: Medunik USA - Key customers
86: Medunik USA - Segment focus
87: Novartis AG - Overview
88: Novartis AG - Business segments
89: Novartis AG - Key offerings
90: Novartis AG - Key customers
91: Novartis AG - Segment focus
92: Pfizer Inc. - Overview
93: Pfizer Inc. - Business segments
94: Pfizer Inc. - Key offerings
95: Pfizer Inc. - Key customers
96: Pfizer Inc. - Segment focus
97: Currency conversion rates for US$
98: Research Methodology
99: Validation techniques employed for market sizing
100: Information sources
101: List of abbreviations